-
Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial
•
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands, and Suzhou (China), has announced positive topline results from its phase III clinical trial of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG). The pivotal clinical study, designed to confirm the efficacy and…
-
BGI Group Subsidiaries Added to US Trade Blacklist by Commerce Department
•
The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37 companies from various countries and industries to its trade blacklist, including 28 Chinese entities. Among the China-based companies are three subsidiaries of genomics giant BGI Group: BGI Research, BGI Tech Solutions (Hongkong) Co., Ltd, and…
-
Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office
•
Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new office in the Cambridge Innovation Centre (CIC) on March 2, 2023. This strategic move marks a significant step forward in expanding the company’s global footprint and enhancing its capabilities to serve and collaborate with biotechs…
-
Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status from the Center for Drug Evaluation (CDE) for its Dupixent (dupilumab) to treat prurigo nodosa (PN) in adults. This marks another significant breakthrough in the type 2 inflammation field, following the drug’s indication approval for…
-
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
•
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese market. The drug is being commercialized by domestic firm Innovent Biologics Inc. (HKEX: 01801) under a partnership deal signed between the two companies in March last year. This collaboration aims to bring innovative treatments to…
-
QL Biopharm Raises Series B Funding for Protein Drug Development
•
QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100 million (USD 14.46 million) in a Series B financing round. The round was led by Bluerun Ventures, with additional participation from Taizhou Pharmaceutical Hi-tech Zone Huayin Financial Investment, Lichen Private Equity Fund, and Mingfeng Capital.…
-
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for HB0025, an in-house developed bispecific antibody (BsAb) targeting programmed-death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF). The BsAb will be assessed in combination…
-
Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its adebrelimab (SHR-1316), a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb). The molecule is now approved for use in combination with chemotherapy to treat first-line extensive stage small-cell lung…
-
Siyi Intelligence Raises Series A Funding for Neural Rehabilitation Solutions
•
Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close to RMB 100 million (USD 14.46 million) in a Series A financing round. The round was led by Chengdu Tianfu International Bio-town’s fund, with additional contributions from Tao Capital. The proceeds will be directed towards…
-
Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its bevacizumab biosimilar. The approved indications for the biosimilar include the treatment of metastatic colorectal cancer (CRC), recurrent glioblastoma, and advanced metastatic or recurrent non-small cell lung cancer (NSCLC).…
-
Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing for its 9MW3911, a non-IL-2 blocking CD25 monoclonal antibody (mAb) developed via the high-efficiency B lymphocyte screening platform, has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication for this…
-
Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study
•
China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully enrolled in a confirmatory study in China for its Liwen RF ablation system, designed for the treatment of hypertrophic cardiomyopathy (HCM). This marks a significant step forward in the clinical development of this innovative device.…
-
PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices
•
PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by Kangju Venture Capital and Tsinghua Innovation Ventures. The proceeds will be directed towards clinical studies and the development of new product…
-
HKUST and PhIRDA Sign MoU to Establish Innovation Centers
•
The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and Research Development Association (PhIRDA) have signed a Memorandum of Understanding (MoU) aimed at establishing two innovation and research centers. This strategic partnership seeks to leverage HKUST’s strengths in basic research and PhIRDA’s members’ capabilities in…
-
ClinChoice Acquires Cromsource to Expand Global CRO Footprint
•
Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l., a CRO operating out of Verona, Italy, and North Carolina in the US. Cromsource, founded in 1997, is a full-service, ISO-certified service provider that supports biotechs, pharmas, and medical device companies. Financial details of the…
-
Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment
•
China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from a Phase IIa clinical study for its lead product, ABP-671. The randomized, double-blind, placebo-controlled trial enrolled 54 patients with gout or hyperuricemia across six cohorts, with 7 randomized to ABP-671 and 2 to placebo per…
-
Echo Biotech Secures Series A++ Funding for Exosomes Drug Development
•
Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi in a Series A++ financing round. The round was led by ZBJL Capital and Yanrui Asset Management, with participation from existing investor Baidu Venture. The proceeds will be directed towards the iteration of Echo Biotech’s…
-
AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL
•
AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion of the first patient implantation in the regulatory clinical trial for its MINI WELL progressive Extended Depth-of-Focus (EDOF) intraocular lens (IOL). The procedure was successfully conducted at the EYE & ENT Hospital of Fudan University…
-
CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a randomized, open, positive controlled, multi-center Phase III study. The study is designed to assess the efficacy and safety of its mitoxantrone hydrochloride liposome in patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) when combined with…
-
TinKer Bio Raises Series A+ Funding for Microfluidic Chip Expansion
•
China-based Hangzhou TinKer BioTechnology Co., Ltd, a leading microfluidic chip technology platform company, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The funds will be directed towards manufacturing plant construction, CDMO business expansion, new technology and process research and development, and manufacturing capacity expansion.…
